Jiangxi Province Key Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
The Second Clinical Medical School, Nanchang University, Nanchang 330006, China.
Exp Biol Med (Maywood). 2023 Feb;248(3):201-208. doi: 10.1177/15353702221142614. Epub 2023 Jan 4.
This study set out to investigate the clinical significance of serum tumor necrosis factor receptor-associated protein 1 (TRAP1) in diagnosing small cell lung cancer (SCLC) with different clinical stages, and to compare the diagnostic efficiency with neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). Besides, to analyze the role of serum TRAP1 in tumor immunity. A total of 91 patients with SCLC, 99 patients with non-small cell lung cancer (NSCLC), 102 patients with pulmonary nodules (PN), and 75 healthy people were included. The concentrations of serum TRAP1 was detected by enzyme-linked immunosorbent assay (ELISA). NSE, CEA, and CA19-9 were detected by chemiluminescence. The results showed that level of TRAP1 in Group SCLC was lower than other three groups ( < 0.01), whereas NSE in SCLC was significantly higher than the others ( < 0.01), and the levels of CEA and CA19-9 were higher than healthy people and PN patients ( < 0.01). There was a significant difference in TRAP1 levels between patients with limited-stage disease SCLC (LD-SCLC) and extensive-stage disease SCLC (ED-SCLC) ( < 0.0001). The sensitivity and specificity of TRAP1 in diagnosing LD-SCLC were 0.964 and 0.560, respectively, and the area under the curve (AUC) was 0.819. The sensitivity and specificity in diagnosing ED-SCLC were 0.810 and 0.868, respectively, and the AUC was 0.933, which showed high diagnostic value. The AUC of these two groups can be increased to 0.946 and 0.947 in combination of four biomarkers, effectively improving the diagnosis rate of SCLC. Our findings have revealed that serum TRAP1 has high diagnostic value for SCLC and high diagnostic sensitivity for LD-SCLC. It is a potential biomarker for SCLC. Combined detection can effectively improve the diagnosis rate of SCLC. TRAP1 may be secreted into the circulation by mature immune cells and participates in tumor immunity as a carrier of tumor antigens.
本研究旨在探讨血清肿瘤坏死因子受体相关蛋白 1（TRAP1）在诊断不同临床分期小细胞肺癌（SCLC）中的临床意义，并与神经元特异性烯醇化酶（NSE）、癌胚抗原（CEA）和糖类抗原 19-9（CA19-9）进行比较。此外，还分析了血清 TRAP1 在肿瘤免疫中的作用。共纳入 91 例 SCLC 患者、99 例非小细胞肺癌（NSCLC）患者、102 例肺结节（PN）患者和 75 名健康人。采用酶联免疫吸附试验（ELISA）检测血清 TRAP1 浓度，采用化学发光法检测 NSE、CEA 和 CA19-9。结果显示，SCLC 组 TRAP1 水平低于其他三组（ < 0.01），SCLC 组 NSE 明显高于其他三组（ < 0.01），CEA 和 CA19-9 水平高于健康人和 PN 患者（ < 0.01）。局限期 SCLC（LD-SCLC）和广泛期 SCLC（ED-SCLC）患者 TRAP1 水平差异有统计学意义（ < 0.0001）。TRAP1 诊断 LD-SCLC 的灵敏度和特异度分别为 0.964 和 0.560，曲线下面积（AUC）为 0.819。诊断 ED-SCLC 的灵敏度和特异度分别为 0.810 和 0.868，AUC 为 0.933，具有较高的诊断价值。四项标志物联合后，两组的 AUC 可提高至 0.946 和 0.947，可有效提高 SCLC 的诊断率。本研究结果表明，血清 TRAP1 对 SCLC 具有较高的诊断价值，对 LD-SCLC 具有较高的诊断灵敏度，是 SCLC 的潜在标志物，联合检测可有效提高 SCLC 的诊断率，TRAP1 可能作为肿瘤抗原的载体，由成熟免疫细胞分泌至循环中，参与肿瘤免疫。
